MassHealth Drug Utilization Review (DUR) Program

(800) 745-7318 (phone)

(877) 208-7428 (fax)

DUR BOARD MEETING (REMOTE)

Quarterly Meeting

June 8, 2022

AGENDA

1. Welcome and Introductory Remarks
2. Resident Research Project: A Pre-Post Evaluation of Health Care Utilization and Costs Among Patients with Asthma Initiating Dupilumab in a Medicaid Population

This an overview of a research project developed by current pharmacy practice residents.

1. Resident Research Project: Changes in Healthcare Resource Utilization Following Initiation of Ustekinumab in Members with Inflammatory Bowel Disease in a Medicaid Population

This an overview of a research project developed by current pharmacy practice residents.

1. Oncology Products: Indication Market Withdrawals

This overview will describe the pharmacy program response to the removal from the market of products which have received accelerated approval in the oncology therapeutic space.

1. MHDL Update

The MHDL Overview includes new additions, changes in Prior Authorization (PA) status, and related attachment updates to be implemented with a recent publication rollout.

1. DUR Operational Update

The DUR Operational Overview includes statistics associated with Prior Authorization (PA) review and PA response, and Call Center metrics

1. MassHealth Update

The MassHealth Update is a brief summary of recent developments in MassHealth in the context of pharmacy, managed care, or public health.

1. Open Forum
2. Narcolepsy Agents Quality Assurance Analysis

This overview is an evaluation of current medical literature and will provide a brief overview of new guideline recommendations in this disease state.

*(time permitting)*

*Zoom link:* <https://umassmed.zoom.us/j/92618015709?pwd=ZHhQVHR0OGhtVFR3QW5mUTM3V3dhdz09>

*Time: 6:00 p.m. – 8:00 p.m.*

*The Massachusetts Commission for the Deaf and Hard of Hearing will assist with arrangements for a sign language interpreter. The Commission may be reached at (617) 740-1600 VOICE and (617) 740-1700 TTY.*

***Next DUR Board (open meeting): September 14, 2022***